Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Neuroendocrine Tumor Treatment Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Neuroendocrine Tumor Treatment Market Status and Forecast (2016-2027)
      • 1.3.2 Global Neuroendocrine Tumor Treatment Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Neuroendocrine Tumor Treatment Supply by Company

    • 2.1 Global Neuroendocrine Tumor Treatment Sales Value by Company
    • 2.2 Neuroendocrine Tumor Treatment Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Neuroendocrine Tumor Treatment Market Status by Category

    • 3.1 Neuroendocrine Tumor Treatment Category Introduction
      • 3.1.1 Everolimus
      • 3.1.2 Sunitinib
      • 3.1.3 Lu-Dotatate
      • 3.1.4 Lanreotide
      • 3.1.5 Octreotide
    • 3.2 Global Neuroendocrine Tumor Treatment Market by Category
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Neuroendocrine Tumor Treatment Market Status by End User/Segment

    • 4.1 Neuroendocrine Tumor Treatment Segment by End User/Segment
      • 4.1.1 Hospitals
      • 4.1.2 Clinic
      • 4.1.3 Others
    • 4.2 Global Neuroendocrine Tumor Treatment Market by End User/Segment
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Neuroendocrine Tumor Treatment Market Status by Region

    • 5.1 Global Neuroendocrine Tumor Treatment Market by Region
    • 5.2 North America Neuroendocrine Tumor Treatment Market Status
    • 5.3 Europe Neuroendocrine Tumor Treatment Market Status
    • 5.4 Asia Pacific Neuroendocrine Tumor Treatment Market Status
    • 5.5 Central & South America Neuroendocrine Tumor Treatment Market Status
    • 5.6 Middle East & Africa Neuroendocrine Tumor Treatment Market Status

    6 North America Neuroendocrine Tumor Treatment Market Status

    • 6.1 North America Neuroendocrine Tumor Treatment Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Neuroendocrine Tumor Treatment Market Status

    • 7.1 Europe Neuroendocrine Tumor Treatment Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Neuroendocrine Tumor Treatment Market Status

    • 8.1 Asia Pacific Neuroendocrine Tumor Treatment Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Neuroendocrine Tumor Treatment Market Status

    • 9.1 Central & South America Neuroendocrine Tumor Treatment Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Neuroendocrine Tumor Treatment Market Status

    • 10.1 Middle East & Africa Neuroendocrine Tumor Treatment Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Neuroendocrine Tumor Treatment Market Forecast by Category and by End User/Segment

    • 12.1 Global Neuroendocrine Tumor Treatment Sales Value Forecast (2022-2027)
    • 12.2 Global Neuroendocrine Tumor Treatment Forecast by Category
    • 12.3 Global Neuroendocrine Tumor Treatment Forecast by End User/Segment

    13 Global Neuroendocrine Tumor Treatment Market Forecast by Region/Country

    • 13.1 Global Neuroendocrine Tumor Treatment Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Tarveda Therapeutics
      • 14.1.1 Company Information
      • 14.1.2 Neuroendocrine Tumor Treatment Product Introduction
      • 14.1.3 Tarveda Therapeutics Neuroendocrine Tumor Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Progenics Pharmaceuticals, Inc.
      • 14.2.1 Company Information
      • 14.2.2 Neuroendocrine Tumor Treatment Product Introduction
      • 14.2.3 Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Novartis AG
      • 14.3.1 Company Information
      • 14.3.2 Neuroendocrine Tumor Treatment Product Introduction
      • 14.3.3 Novartis AG Neuroendocrine Tumor Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Ispen
      • 14.4.1 Company Information
      • 14.4.2 Neuroendocrine Tumor Treatment Product Introduction
      • 14.4.3 Ispen Neuroendocrine Tumor Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Hutchinson Medipharma Limited
      • 14.5.1 Company Information
      • 14.5.2 Neuroendocrine Tumor Treatment Product Introduction
      • 14.5.3 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Exelixis, Inc.
      • 14.6.1 Company Information
      • 14.6.2 Neuroendocrine Tumor Treatment Product Introduction
      • 14.6.3 Exelixis, Inc. Neuroendocrine Tumor Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Dauntless Pharmaceuticals, Inc.
      • 14.7.1 Company Information
      • 14.7.2 Neuroendocrine Tumor Treatment Product Introduction
      • 14.7.3 Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Advanced Accelerator Applications
      • 14.8.1 Company Information
      • 14.8.2 Neuroendocrine Tumor Treatment Product Introduction
      • 14.8.3 Advanced Accelerator Applications Neuroendocrine Tumor Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Neuroendocrine Tumor Treatment market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Neuroendocrine Tumor Treatment market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Everolimus
      Sunitinib
      Lu-Dotatate
      Lanreotide
      Octreotide

      Segmented by End User/Segment
      Hospitals
      Clinic
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Tarveda Therapeutics
      Progenics Pharmaceuticals, Inc.
      Novartis AG
      Ispen
      Hutchinson Medipharma Limited
      Exelixis, Inc.
      Dauntless Pharmaceuticals, Inc.
      Advanced Accelerator Applications
      Buy now